Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality
| Autor: | Ying Teo, Michael R. Ardern-Jones, Hang Tt Phan, Andrew S Duncombe, Trevor Smith, Matt Stammers, Anastasia Koutalopoulou, James Batchelor, Florina Borca |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Excess mortality
medicine.medical_specialty Scoring system Coronavirus disease 2019 (COVID-19) business.industry SARS-CoV-2 Incidence (epidemiology) Incidence COVID-19 rapid report COVID-19 General Medicine Odds ratio Lymphohistiocytosis Hemophagocytic Cohort Studies Older patients Internal medicine Cohort medicine Humans business Cohort study Aged |
| Zdroj: | Clin Med (Lond) |
| Popis: | A significant proportion of COVID-19 patients show evidence of hyperinflammation (HI), of which secondary haemophagocytic lymphohistiocytosis (sHLH) is the most severe manifestation and diagnosed with HScore. Using a COVID-relevant modification of the HScore (%HScore), we set out to determine the prevalence of sHLH in 567 COVID-19 inpatient cases. The overall incidence of individuals with an 80% probability of sHLH in our COVID-19 cohort was 1.59% on admission and only rose to 4.05% if calculated at any time during admission. This small cohort as defined by %HScore showed no excess mortality compared with the whole cohort. Overall, %HScores were lower in older patients (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|